Biotech News

Halozyme Therapeutics Presents Positive Pre-Clinical Single Agent Data for PEGPH20

Halozyme Therapeutics, Inc. (HALO)Halozyme Therapeutics, Inc.FDA / regulatory

Significant Single Agent Anti-Tumor Activity Observed With PEGPH20 in Tumor Models That Accumulate Hyaluronan Extended Half-Life of PEGPH20 Allows Continued Depletion of Hyaluronan From Tumors Following Systemic Administration SAN DIEGO, Jan. 26, 2009 (GLOBE NEWSWIRE) -- Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the presentation of positive pre-clinical animal efficacy data for PEGPH20 (pegylated-rHuPH20 enzyme) monotherapy at the American Association for Cancer Research (AACR) Advances in Prostate Cancer Research meeting in San Diego. The study demonstrated that repeat intravenous treatment with PEGPH20 as a single agent in the PC3 mouse model resulted in approximately 70% (p=0.001) tumor growth inhibition compared to controls.

"This study demonstrates that a sustained depletion of hyaluronan from the tumor microenvironment with PEGPH20 is associated with a suppression of tumor cell expansion," stated Gregory Frost, Ph.D., Halozyme's Chief Scientific Officer. "By treating the tumor as an organ rather than just individual cancer cells, novel complementary approaches to treating this disease may be possible."

Halozyme continues to prepare for the commencement of a Phase 1 single agent clinical trial during the first half of 2009 with intravenously administered PEGPH20 in treatment refractory cancer patients. Additional investigations are also underway to explore combinations of PEGPH20 with other targeted and cytotoxic agents for potential clinical investigation.

Additional Study Results and Details

Various prostate cancer cell lines were screened in vitro for the production of pericellular coats comprised of hyaluronan (HA), the substrate for the PEGPH20 enzyme. Several aggressive prostate cancer cell lines that produce HA-rich coats surrounding the tumor cells collapsed in the presence of PEGPH20. Moreover, PEGPH20 significantly suppressed the growth of coat producing human prostate cancer cells within a three-dimensional matrix in a dose dependent fashion, suggesting such cells require HA to rapidly expand into the surrounding microenvironment.

Treatment of human PC3 prostate tumors in athymic mice with intravenous PEGPH20 resulted in a rapid, dose-dependent depletion of HA from the tumor microenvironment. Accumulation of HA in tumors such as PC3, correlates with increased tumor growth, metastases and elevated interstitial fluid pressure. Continued enzymatic depletion of HA from PC3 tumors with intravenous PEGPH20 was associated with a 70% tumor growth inhibition and an approximate doubling in time to progression. In contrast, no suppression of tumor volume growth or increase in time to progression was observed with PEGPH20 treatment of an HA negative prostate tumor, Du145.

Pegylation refers to the covalent attachment of polyethylene glycol to a molecule, usually a drug or therapeutic protein. The pegylation of rHuPH20 increases its plasma half-life to greater than 24 hours compared to less than one minute for the unpegylated enzyme, therefore resulting in a longer duration of action.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(tm) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID. Halozyme's research pipeline candidates target significant areas of unmet medical need. For more information visit www.halozyme.com .

The Halozyme Therapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5750

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning future clinical trials and benefits associated with PEGPH20) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Related news

GSKGSK plc2026-11-17 18:50 EST

Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer

KPTIKaryopharm Therapeutics2026-11-17 12:30 EST

Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO® (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis

REGNRegeneron Pharmaceuticals2026-11-17 12:00 EST

Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications

IDYAIDEAYA Biosciences2026-11-16 21:05 EST

IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

TEVATeva Pharmaceutical Industries2026-11-16 13:00 EST

U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

ANGOAngioDynamics2026-10-21 12:30 EST

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

GSKGSK plc2026-10-20 17:42 EST

Hibsago (bepirovirsen) approved in the US for the treatment of chronic hepatitis B (CHB)

URGNUroGen Pharma2026-10-19 12:00 EST

UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC

REGNRegeneron Pharmaceuticals2026-10-16 11:00 EST

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

Halozyme Therapeutics, Inc.

Drug-Delivery Technology Company Halozyme develops and licenses technologies that improve how biologic medicines are formulated and administered. Its business is based on platform access fees, development milestones, product supply, and royalties from partner medicines rather than ownership of most underlying therapeutic...

Recent company news

Stock data

Close
93.04 USD
Market cap
7.86B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States